SCHEMBL5027769

SCHEMBL5027769

O=C(Cc1cnc(NC(c2ccccc2)(c2ccccc2)c2ccccc2)s1)Nc1ccc(F)c(Cl)c1

nearest known ligand 0.45

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
TSHR P16473 2/20 0.45
NPC1 O15118 2/20 0.44
RAB9A P51151 1/20 0.44
FABP4 P15090 1/20 0.43
SMN1; SMN2 Q16637 1/20 0.43
LMNA P02545 3/20 0.42
MEN1 O00255 3/20 0.42
KMT2A Q03164 3/20 0.42
MAPT P10636 1/20 0.42
KDM4E B2RXH2 1/20 0.42
AURKA O14965 1/20 0.42
AURKB Q96GD4 1/20 0.42
PIK3CD O00329 1/20 0.41
PIK3CA P42336 1/20 0.41
PIK3CB P42338 1/20 0.41
TP53 P04637 1/20 0.40
HTT P42858 1/20 0.40
CCNE1 P24864 1/20 0.40
CDK2 P24941 1/20 0.40
CDK5 Q00535 1/20 0.40

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5025190 0.91 SMN1; SMN2 (0.42) TSHRNPC1RAB9ASMN1; SMN2LMNA
SCHEMBL5029591 0.87 KCNJ5 (0.47) NPC1RAB9ALMNAMEN1KMT2A
SCHEMBL5027736 0.85 AURKA (0.49) NPC1RAB9ASMN1; SMN2LMNAMEN1
SCHEMBL5026015 0.85 CCNE1 (0.44) TSHRSMN1; SMN2MEN1KMT2AMAPT
SCHEMBL5045081 0.82 CCNE1 (0.42) SMN1; SMN2MEN1KMT2AMAPTTP53
SCHEMBL5046778 0.79 CCNE1 (0.45) TSHRNPC1RAB9ASMN1; SMN2LMNA
SCHEMBL5025301 0.78 TSHR (0.53) TSHRNPC1FABP4SMN1; SMN2MEN1
SCHEMBL5025993 0.76 SCD (0.45) TSHRNPC1RAB9ASMN1; SMN2LMNA
SCHEMBL27543447 0.72 ALDH1A1 (0.51) TSHRNPC1RAB9ASMN1; SMN2LMNA
SCHEMBL5041435 0.69 AURKA (0.53) TSHRNPC1RAB9ASMN1; SMN2MEN1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1299381-B1 SUBSTITUTED QUINAZOLINE DERIVATIVES AND THEIR USE AS INHIBITORS ASTRAZENECA AB (SE) 2008-05-07 EP disclosed
WO-2002000649-A9 SUBSTITUTED QUINAZOLINE DERIVATIVES AND THEIR USE AS INHIBITORS ASTRAZENECA AB (SE) 2007-09-20 WO disclosed
US-20060046987-A1 Substituted quinazoline derivatives and their use as inhibitors ASTRAZENECA AB (SE) 2006-03-02 US disclosed
US-6919338-B2 Substituted quinazoline derivatives and their use as inhibitors of aurora-2 kinase ASTRAZENECA AB (SE) 2005-07-19 US disclosed
US-20030187002-A1 Substituted quinazoline derivatives and their use as inhibitors ASTRAZENECA AB (SE) 2003-10-02 US disclosed
EP-1299381-A1 SUBSTITUTED QUINAZOLINE DERIVATIVES AND THEIR USE AS INHIBITORS AstraZeneca AB (SE) 2003-04-09 EP disclosed
WO-2002000649-A1 SUBSTITUTED QUINAZOLINE DERIVATIVES AND THEIR USE AS INHIBITORS ASTRAZENECA AB (SE) 2002-01-03 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20060046987-A1 Substituted quinazoline derivatives and their use as inhibitors AURKA, AURKB, AURKC TSHR 2960/4885NPC1 2593/4885RAB9A 2905/4885
US-20030187002-A1 Substituted quinazoline derivatives and their use as inhibitors AURKA, AURKC, AURKB TSHR 3868/4885NPC1 1551/4885RAB9A 1702/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.